A Randomized, Double-blind, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of SYS6012 VS secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: a295d47b3bd84ca9efa87b4fd9069d1bdf5b72f4
First added on: Apr 22, 2026